Pharmaceutical

Why pharma is still far from a treatment for galactosemia

With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia treatment are low.

Mar 1, 2025 - 06:00
Why pharma is still far from a treatment for galactosemia
With issues in therapy delivery and a barren trial landscape, short-term chances for a commercial galactosemia treatment are low.
Read the original article

Tags:

Previous Article

Medigene and EpimAb to develop T cell engagers for solid tumours

Next Article

FDA accepts Sobi’s Gamifant application for HLH/MAS treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

‘A target on my back’: New survey shows racism is a huge problem in nursing

‘A target on my back’: New survey shows racism is a hug...

May 31, 2023

Australia lists new medicines for GVHD and chronic rhinosinusitis

Australia lists new medicines for GVHD and chronic rhin...

Apr 10, 2023

Rare disease treatments skipping UK patients largely due to costs, survey shows

Rare disease treatments skipping UK patients largely du...

Mar 1, 2025